Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612000949886
Ethics application status
Approved
Date submitted
5/09/2012
Date registered
5/09/2012
Date last updated
25/11/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
Mepitel Film for the prevention of skin ulceration caused by radiation therapy in breast cancer patients.
Query!
Scientific title
The efficacy of Mepitel Film in preventing radiation-induced moist desquamation in breast cancer patients.
Query!
Secondary ID [1]
281168
0
NA
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast cancer patients treated with radiation
287334
0
Query!
Acute side effects of radiation therapy for breast cancer
287335
0
Query!
Condition category
Condition code
Cancer
287671
287671
0
0
Query!
Breast
Query!
Skin
287672
287672
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Patients who are to be treated with radiation therapy for breast cancer will be invited to particiate in this trial.
At the start of radiation treatment the chest area to be irradiated will be divided into a medial and lateral half (containing the axilla). Each half will be randomized to either the treatment or the control arm.
Treatment Arm
1. Mepitel Film will be placed on the skin area randomized to the treatment arm by the research radiation therapist. Film will be replaced when necessary (approximately every 1 or 2 weeks).
2. Radiation therapy will be given through the Film, due to the extremely small bolus effect.
3. The Film will remain in place for the duration of RT treatment and after completion of radiation therapy treatment until the skin reactions resolve fully.
Control Arm
1. Aqueous cream will be applied by the patient twice a day to treat the control skin areas.
Trial Endpoint: moist desquamation
When moist desquamation occurs in either the Mepitel Film or control patches, the skin will be treated as per department protocol.
Query!
Intervention code [1]
285617
0
Prevention
Query!
Comparator / control treatment
Aqueous cream will be applied by the patient twice a day to treat the control skin areas for the entire duration of the trial (from the first day of treatment till resolution of all skin reactions).
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
287914
0
Incidence of moist desquamation. Moist desquamation is when the integrity of the epidermis is lost, leading to ulceration. We will use the RISRAS scale to assess all skin reactions, including moist desquamation. This Radiation-Induced Skin Reaction Assessment Scale was developed specifically for these situations by Noble Adams (Br J Nurs. 1999 Nov;8(19):1305-12) and later adjusted by McBride et al. (Cancer Nurs. 2008 Jan-Feb;31(1):E8-14).We have used this scale in our previous two trials (Diggelmann et al. BJR, 83 (2010), 971?978).
Query!
Assessment method [1]
287914
0
Query!
Timepoint [1]
287914
0
The number of skin patches in the treatment and control arms that develop moist desquamation during the trial.
The trial commences at the time that the patients will get their very first radiation therapy treatment. Treatment usually lasts 5 weeks. Patients will continue to be seen once a week for four weeks after completion of treatment or untill all skin reactions have been resolved.
Query!
Secondary outcome [1]
299046
0
Time to developing moist desquamation. Moist desquamation will be assessed under primary outcome 1.
Query!
Assessment method [1]
299046
0
Query!
Timepoint [1]
299046
0
The number of days it takes to develop moist desquamation in skin patches in the treatment and control arms after commencement of radiation treatment.
Query!
Secondary outcome [2]
301101
0
The severity of the skin reactions which will be determined by RISRAS.
Query!
Assessment method [2]
301101
0
Query!
Timepoint [2]
301101
0
RISRAS scores will be determined three times a week during treatment and once a week after completion of treatment until skin reacyions resolve (usually 4-6 weeks after treatment completion)
Query!
Eligibility
Key inclusion criteria
Patients who receive radiation therapy for breast cancer.
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Previous radiation therapy to the chest
Metastatic disease
Inability to attend follow up sessions
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
1. Patients will commence RT treatment after having received information about the trial verbally from the radiation oncologist and research radiation therapist and in the form of the participant information sheet. They will also give written informed consent .
2. At the start of treatment the chest area to be irradiated will be divided into a medial and lateral half (containing the axilla). Each half will be randomized to either the treatment or the control arm.
3. Randomization will be done by the PI, Dr Patries Herst from the University of Otago, Wellington, using computer generated random numbers, provided by the University’s biostatistician, Dr James Stanley.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated numbers.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Patients will act as their own controls. This circumvents confounding patient-related and treatment-related factors. Randomization will circumvent the effect of small dose differences between the areas with dressings and the areas without dressings. In addition, TLDs will be used on all patients to determine the actual dose received by skin areas covered in Film and those treated with aqueous cream.
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
24/10/2012
Query!
Actual
24/10/2012
Query!
Date of last participant enrolment
Anticipated
1/06/2013
Query!
Actual
30/04/2013
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
80
Query!
Recruitment outside Australia
Country [1]
4533
0
New Zealand
Query!
State/province [1]
4533
0
South Island, Dunedin
Query!
Funding & Sponsors
Funding source category [1]
285942
0
Commercial sector/Industry
Query!
Name [1]
285942
0
Molnlycke Healthcare Ltd
Query!
Address [1]
285942
0
Molnlycke Healthcare
Box 130 80
SE-402 52 Gothenburg
Sweden
Query!
Country [1]
285942
0
Sweden
Query!
Primary sponsor type
University
Query!
Name
University of Otago
Query!
Address
POBox 7343
Wellington South
Wellington 6242
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
284766
0
Hospital
Query!
Name [1]
284766
0
Dunedin Hospital
Query!
Address [1]
284766
0
Southern DHB
Private Bag 1921
Dunedin 9054
Query!
Country [1]
284766
0
New Zealand
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
287974
0
University of Otago Human Ethics Committee
Query!
Ethics committee address [1]
287974
0
University of Otago
Academic Committees
PO Box 56,
Dunedin 9054,
New Zealand
Query!
Ethics committee country [1]
287974
0
New Zealand
Query!
Date submitted for ethics approval [1]
287974
0
04/09/2012
Query!
Approval date [1]
287974
0
24/10/2012
Query!
Ethics approval number [1]
287974
0
12/239
Query!
Summary
Brief summary
Breast cancer is the most common malignancy for women in New Zealand. Severe skin reactions occur in a significant proportion of women who receive radiation therapy for breast cancer. Skin ulceration affects patient quality of life and poses a risk of infection. There is currently no standard treatment for radiation-induced skin reactions.
We have shown in two trials in New Zealand that Mepilex Lite dressings decrease the severity of acute radiation-induced skin reactions. Both trials were intra-patient controlled randomized trials, whereby each patient acted as their own control, circumventing the problem of the many confounding treatment-and patient-related factors that affect the severity of such skin reactions.
However, the dressing were not transparent and did not stick well in the armpit and underneath the breast.
Mepitel Film has all the advantages of Mepilex Lite but is transparent, sticks better and stays on for longer. This study will compare the efficacy of Mepitel Film with that of aqueous cream in reducing the incidence of radiation-induced skin ulceration in 40 women treated for breast cancer.
Query!
Trial website
Query!
Trial related presentations / publications
The trial has recently been published:
Patries M Herst, Noelle C Bennett, Annie E Sutherland, Ruth I Peszynski, Dean B Paterson & Marieke L Jasperse. Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients. Radiotherapy and Oncology. 2014. 110(1) pp. 137-143).
Query!
Public notes
Query!
Attachments [1]
8
8
0
0
/AnzctrAttachments/362989-Herst et al., 2014.pdf
Query!
Query!
Contacts
Principal investigator
Name
34667
0
Dr Patries Herst
Query!
Address
34667
0
University of Otago POBox 7343 Wellington South Wellington 6242.
Query!
Country
34667
0
New Zealand
Query!
Phone
34667
0
+64 4 3855475
Query!
Fax
34667
0
+64 4 3855375
Query!
Email
34667
0
[email protected]
Query!
Contact person for public queries
Name
17914
0
Dr Patries Herst
Query!
Address
17914
0
Radiation Therapy
Senior Lecturer
University of Otago
POBox 7343
Wellington South
Wellington 6242
Query!
Country
17914
0
New Zealand
Query!
Phone
17914
0
+64 4 3855475
Query!
Fax
17914
0
+64 4 3855375
Query!
Email
17914
0
[email protected]
Query!
Contact person for scientific queries
Name
8842
0
Dr Patries Herst
Query!
Address
8842
0
Radiation Therapy
Senior Lecturer
University of Otago
POBox 7343
Wellington South
Wellington 6242
Query!
Country
8842
0
New Zealand
Query!
Phone
8842
0
+64 4 3855475
Query!
Fax
8842
0
+64 4 3855375
Query!
Email
8842
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF